Evidence map›Paper›PMID 42825038›Full record

ArticleThe journal of liquid biopsy2026

Comparative diagnostic value of a blood-based three-gene DNA methylation assay and a seven-autoantibody panel for differentiating pulmonary nodules.

Dong Rui, Xunsi Liang, Min Yi, Shaowei Zhan, Shui Xiang, Jifei Chen, Jiachen Hou, Xin Wu, Xuejun Qin, Zhougui Ling

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dong RuiDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Xunsi LiangDepartment of Thoracic Surgery, Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, Guangxi, China.
Min YiThe Pathology Department of the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Shaowei ZhanDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Shui XiangDepartment of Thoracic Surgery, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Jifei ChenDepartment of Thoracic Surgery, Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, Guangxi, China.
Jiachen HouDepartment of Medical Imaging, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Xin WuDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Xuejun QinDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Zhougui LingDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Low-dose CT has increased pulmonary nodule detection, but noninvasively distinguishing benign from malignant nodules or early lung cancer remains difficult. Blood-based DNA methylation and tumour-associated autoantibody assays may complement imaging. Methods: This combined prospective and retrospective study evaluated two blood-based strategies. The prospective methylation cohort (141 participants; May 2024-April 2026) comprised 91 malignant, 22 benign-nodule, and 28 high-risk individuals, with plasma Results: Positive rates in the malignant versus benign versus high-risk groups were 83.52% vs 45.45% vs 10.71% for the three-methylation panel and 63.20% vs 16.95% vs 10.37% for the seven-autoantibody panel (both Conclusions: Both panels aided differentiation of malignant from benign pulmonary nodules; methylation gave the strongest early-stage sensitivity and autoantibodies higher specificity, both outperforming conventional markers. Combined testing may improve sensitivity but requires multicentre validation.

Indexed as

DNA methylationLiquid biopsyLung cancerPulmonary noduleTumour-associated autoantibody

Identifiers

PMID42825038
PMCPMC13628671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.